

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**  
**北京同仁堂國藥有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 3613)**

**RETIREMENT OF EXECUTIVE DIRECTOR,  
THE CHAIRMAN OF THE BOARD AND  
AUTHORISED REPRESENTATIVE  
AND  
APPOINTMENT OF AUTHORISED REPRESENTATIVE**

**RETIREMENT OF EXECUTIVE DIRECTOR, THE CHAIRMAN OF THE BOARD AND  
AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) hereby announces that with effect from 31 August 2023, Ms. Ding Yong Ling (“**Ms. Ding**”) has retired as the executive director of the Company, the chairman of the Board and authorised representative of the Company due to Ms. Ding has reached the retirement age.

Ms. Ding has confirmed that she has no disagreement with the Board or the Company and there is no matter in relation to her retirement that needs to be brought to the attention of shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

During her tenure of service at the Company, Ms. Ding faithfully performed her duties and contributed to the Company's development and enhanced the Company's sustainability. The Board would like to take this opportunity to express its sincere gratitude to Ms. Ding for her invaluable contribution.

Following the retirement of Ms. Ding, the Company does not have a chairman of the Board and deviates from paragraph C.2 of the Corporate Governance Code set out in Appendix 14 of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”). The Company will identify a suitable candidate to fill the vacancy of the chairman of the Board as soon as practicable and will make further announcement as and when appropriate.

## **APPOINTMENT OF AUTHORISED REPRESENTATIVE**

The Board further announces that Mr. Chen Fei, an executive director and the executive deputy general manager of the Company, has been appointed as an authorised representative of the Company under Rule 3.05 of the Listing Rules with effect from 31 August 2023.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Chen Fei**  
*Executive Director*

Hong Kong, 31 August 2023

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Mr. Chen Fei  
Ms. Lin Man

***Non-executive Director:***

Ms. Feng Li

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Xu Hong Xi  
Mr. Chan Ngai Chi